Miki Yamada-Hara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Miki Yamada-Hara has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Arisachi Tanaka
Biomedical Sciences Graduate Program, University of California San Diego, La Jolla, CA, USA
22 shared publications - David Schwartz
Cell IDx, Inc. (a Division of Leica Biosystems), San Diego, California
22 shared publications - Eyal Raz
University of California, San Diego
22 shared publications - Han Chang
Division of Rheumatology, Autoimmunity, and Inflammation, Department of Medicine, University of California San Diego, La Jolla, California
22 shared publications - Jack Heath
Leica Biosystems, Vista, California
22 shared publications - Ji Won Byun
Department of Dermatology Inha University School of Medicine Incheon Republic of Korea
22 shared publications
Latest Publications
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from RORγt Inhibition Reduces Protumor Inflammation and Decreases Tumor Growth in Experimental Models of Lung Cancer
Supplementary Figure S8. The RORγ/γt inhibitors digoxin and SR2211 inhibit Th17 cell differentiation in vitro.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from RORγt Inhibition Reduces Protumor Inflammation and Decreases Tumor Growth in Experimental Models of Lung Cancer
Supplementary Figure S8. The RORγ/γt inhibitors digoxin and SR2211 inhibit Th17 cell differentiation in vitro.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S15 from RORγt Inhibition Reduces Protumor Inflammation and Decreases Tumor Growth in Experimental Models of Lung Cancer
Supplementary Figure S15. Effect of digoxin treatment on cytokine expression in urethane-treated Rag1–/– mice.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S15 from RORγt Inhibition Reduces Protumor Inflammation and Decreases Tumor Growth in Experimental Models of Lung Cancer
Supplementary Figure S15. Effect of digoxin treatment on cytokine expression in urethane-treated Rag1–/– mice.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from RORγt Inhibition Reduces Protumor Inflammation and Decreases Tumor Growth in Experimental Models of Lung Cancer
Supplementary Figure S3. Pharmacological inhibition of RORγ/γt does not affect the expression of cell proliferation, cell death, or cell survival markers in a Kras-mutated mouse LC cell line.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from RORγt Inhibition Reduces Protumor Inflammation and Decreases Tumor Growth in Experimental Models of Lung Cancer
Supplementary Figure S3. Pharmacological inhibition of RORγ/γt does not affect the expression of cell proliferation, cell death, or cell survival markers in a Kras-mutated mouse LC cell line.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Data from RORγt Inhibition Reduces Protumor Inflammation and Decreases Tumor Growth in Experimental Models of Lung Cancer
The retinoic acid receptor–related orphan receptor C (RORC) gene encodes two isoforms, RORγ and RORγt, which function as transcription factors in different cell types. RORγt is expressed in specific immune cells involved in inflammatory responses, whereas RORγ is found in parenchymal cells, in which it participates in metabolism and circadian rhythm regulation. Although the roles of RORγt in CD4+ Th17 lymphocytes and RORγ in certain cancer cell types are increasingly recognized, their relative contributions to lung cancer development remain unclear. In this study, we investigated the roles of RORC, RORγ, and RORγt in lung cancer using mouse models and human data from The Cancer Genome Atlas. We evaluated the effects of Rorc gene deletion and RORγ/γt pharmacologic inhibition in cancer and immune cells in vitro and in vivo. Pharmacologic blockade of RORγ/γt with digoxin significantly reduced lung cancer development in two mouse models: a KrasG12D-driven genetic model and a urethane-induced chemical model. Mechanistically, this effect was mediated by inhibition of RORγt in specific immune cells, such as type 3 innate lymphoid cells and Th17 cells, rather than by inhibiting RORγ in tumor cells. This reduced the production of proinflammatory cytokines, including IL17A, IL17F, and IL22, and decreased tumor cell proliferation. Additionally, The Cancer Genome Atlas analysis revealed that elevated RORC expression is associated with an altered tumor microenvironment and poorer prognosis in patients with lung adenocarcinoma. These findings highlight the therapeutic potential of targeting RORγt to reduce protumor inflammation and propose a strategy for lung cancer treatment.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from RORγt Inhibition Reduces Protumor Inflammation and Decreases Tumor Growth in Experimental Models of Lung Cancer
The retinoic acid receptor–related orphan receptor C (RORC) gene encodes two isoforms, RORγ and RORγt, which function as transcription factors in different cell types. RORγt is expressed in specific immune cells involved in inflammatory responses, whereas RORγ is found in parenchymal cells, in which it participates in metabolism and circadian rhythm regulation. Although the roles of RORγt in CD4+ Th17 lymphocytes and RORγ in certain cancer cell types are increasingly recognized, their relative contributions to lung cancer development remain unclear. In this study, we investigated the roles of RORC, RORγ, and RORγt in lung cancer using mouse models and human data from The Cancer Genome Atlas. We evaluated the effects of Rorc gene deletion and RORγ/γt pharmacologic inhibition in cancer and immune cells in vitro and in vivo. Pharmacologic blockade of RORγ/γt with digoxin significantly reduced lung cancer development in two mouse models: a KrasG12D-driven genetic model and a urethane-induced chemical model. Mechanistically, this effect was mediated by inhibition of RORγt in specific immune cells, such as type 3 innate lymphoid cells and Th17 cells, rather than by inhibiting RORγ in tumor cells. This reduced the production of proinflammatory cytokines, including IL17A, IL17F, and IL22, and decreased tumor cell proliferation. Additionally, The Cancer Genome Atlas analysis revealed that elevated RORC expression is associated with an altered tumor microenvironment and poorer prognosis in patients with lung adenocarcinoma. These findings highlight the therapeutic potential of targeting RORγt to reduce protumor inflammation and propose a strategy for lung cancer treatment.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S16 from RORγt Inhibition Reduces Protumor Inflammation and Decreases Tumor Growth in Experimental Models of Lung Cancer
Supplementary Figure S16. Analysis of IL17A, IL17F, and IL22 promotor methylation and gene expression in LUAD patients.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S16 from RORγt Inhibition Reduces Protumor Inflammation and Decreases Tumor Growth in Experimental Models of Lung Cancer
Supplementary Figure S16. Analysis of IL17A, IL17F, and IL22 promotor methylation and gene expression in LUAD patients.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from RORγt Inhibition Reduces Protumor Inflammation and Decreases Tumor Growth in Experimental Models of Lung Cancer
Supplementary Figure S11. Digoxin treatment does not affect the infiltration of some of the major myeloid cell subsets into the lungs of KrasG12D mice.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from RORγt Inhibition Reduces Protumor Inflammation and Decreases Tumor Growth in Experimental Models of Lung Cancer
Supplementary Figure S11. Digoxin treatment does not affect the infiltration of some of the major myeloid cell subsets into the lungs of KrasG12D mice.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S13 from RORγt Inhibition Reduces Protumor Inflammation and Decreases Tumor Growth in Experimental Models of Lung Cancer
Supplementary Figure S13. Digoxin treatment does not alter the infiltration of M1, M2, or PD-1-expressing tumorassociated macrophages (TAMs) in the lungs of KrasG12D mice.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S13 from RORγt Inhibition Reduces Protumor Inflammation and Decreases Tumor Growth in Experimental Models of Lung Cancer
Supplementary Figure S13. Digoxin treatment does not alter the infiltration of M1, M2, or PD-1-expressing tumorassociated macrophages (TAMs) in the lungs of KrasG12D mice.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from RORγt Inhibition Reduces Protumor Inflammation and Decreases Tumor Growth in Experimental Models of Lung Cancer
Supplementary Table S1. Key resources table.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from RORγt Inhibition Reduces Protumor Inflammation and Decreases Tumor Growth in Experimental Models of Lung Cancer
Supplementary Table S1. Key resources table.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from RORγt Inhibition Reduces Protumor Inflammation and Decreases Tumor Growth in Experimental Models of Lung Cancer
Supplementary Figure S2. mIF panel validation.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from RORγt Inhibition Reduces Protumor Inflammation and Decreases Tumor Growth in Experimental Models of Lung Cancer
Supplementary Figure S2. mIF panel validation.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from RORγt Inhibition Reduces Protumor Inflammation and Decreases Tumor Growth in Experimental Models of Lung Cancer
Supplementary Figure S7. Rorg expression is not increased in CSCs isolated from the lungs of KrasG12D mice.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from RORγt Inhibition Reduces Protumor Inflammation and Decreases Tumor Growth in Experimental Models of Lung Cancer
Supplementary Figure S7. Rorg expression is not increased in CSCs isolated from the lungs of KrasG12D mice.